We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GMED Q3 Earnings Call Highlights Guidance Cut and 2027 Reset
Read MoreHide Full Article
Key Takeaways
Globus Medical cuts its 2026 revenue forecast to $3.09B from $3.18B-$3.22B amid weaker sales trends.
Delayed spine launches, slower sales rep productivity and a 25.7% drop in Nevro sales pressure GMED.
GMED targets 2027 growth from SCRIPT, EIQ and HFX Elite as cost discipline supports its earnings outlook.
Globus Medical, Inc. (GMED - Free Report) lowered its 2026 revenue outlook after delayed spine product launches and a slower Nevro recovery weighed on third-quarter sales. Management shifted attention toward products and sales initiatives expected to contribute in 2027.
The earnings call also underscored a divide between near-term revenue pressure and improving profitability, with executives defending their growth strategy while acknowledging execution shortfalls.
Globus Medical Lowers 2026 Sales Outlook
Chief financial officer Kyle Kline reduced full-year revenue guidance to $3.09 billion from $3.18 billion to $3.22 billion, citing weaker third-quarter sales and early fourth-quarter trends. The revised forecast represents 5.1% annual growth.
Kline reaffirmed non-GAAP diluted earnings guidance of $4.95 to $5.05, supported by cost discipline and operating efficiencies. He said the revenue outlook implies a mid-single-digit sales decline in the fourth quarter.
GMED’s adjusted earnings of $1.23 per share beat the Zacks Consensus Estimate of $1.20. Third-quarter revenues declined to $763.7 million, which missed the Zacks Consensus Estimate of $793 million.
Globus Medical, Inc. Price, Consensus and EPS Surprise
Chief executive officer Keith Pfeil attributed U.S. Spine's 2% growth to difficult comparisons, postponed launches and smaller-than-expected contributions from competitive sales representatives. He acknowledged that execution could have been better.
During questions from BMO Capital Markets, Pfeil declined to quantify the sales lost to delayed launches. He said manufacturing problems had largely been addressed, although smaller issues remained.
A Jefferies analyst asked whether slower market growth had affected results. Pfeil instead emphasized company-specific shortcomings, including the pace of recruiting and the sales transferred by newly hired representatives.
Globus Targets 2027 Product Contributions
Pfeil outlined SCRIPT patient-specific implants and rods, the XLIF Prone Lateral Solution and the forthcoming EIQ product suite as important growth drivers. SCRIPT is available, while the prone-positioning solution is scheduled for later in the fourth quarter.
Kline clarified during the Needham question-and-answer exchange that delayed products would contribute little to 2026 revenue. Their anticipated impact has shifted into 2027.
Asked by TD Cowen about growth expectations, Pfeil described mid- to high-single-digit revenue growth as a goal, not formal 2027 guidance. He expects earnings to outpace revenue growth, although increased research and development spending will offset some margin gains.
GMED Sees Uneven Nevro Recovery
Nevro sales fell 25.7% year over year to $73.7 million and declined 9% sequentially. Pfeil said weaker trial volumes continued to restrain revenue despite substantial rehiring of sales personnel.
Kline reported a 19.9% adjusted EBITDA margin for Nevro, reflecting the benefits of previous restructuring. He said productivity improvements from newly trained representatives should support the recovery.
Pfeil identified HFX Elite, a new implantable pulse generator planned for commercial launch in the first half of 2027, as another potential catalyst. The company also intends to pursue competitive recruiting in the pain business.
Globus Expands Capital Deployment and Cash Returns
Enabling Technologies revenue grew 24% to $34.9 million. Pfeil said combined EGPS robot and eHub navigation deployments rose 73% year over year, including sold, leased and rented units, supporting a more flexible capital model.
Kline cautioned that a shift toward rental and lease arrangements would reduce upfront revenue, particularly against a demanding fourth-quarter comparison. Management expects greater recurring revenues and implant pull-through over time.
The company generated $225 million in quarterly free cash flow and repurchased approximately $143 million of shares. Kline said the board added $500 million to the repurchase authorization, while internal product development remains the first capital allocation priority.
GMED Maintains Its Longer-Term Focus
Pfeil also highlighted 19% growth in Trauma and acquisitions of Higgs Boson and Synaptive assets to develop surgical intelligence and cranial capabilities. He said those acquisitions would not contribute meaningful revenue in 2027.
Management maintained confidence in the broader product and technology strategy, while placing immediate emphasis on launch execution, sales force productivity and stabilizing Nevro. The latest outlook keeps the near-term revenue challenges in focus.
Zacks Rank and Style Scores for GMED
GMED carries a Zacks Rank #2 (Buy), reflecting a favorable earnings-estimate-revision profile under the Zacks ranking framework. Its Value Score of B, Growth Score of A and VGM Score of A indicate favorable characteristics across valuation and growth measures. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Its Momentum Score of D presents a contrasting signal, reflecting weaker momentum characteristics. Although the combination of a top-two Zacks Rank and strong VGM Score is favorable within the framework, the Zacks Rank can change as analysts revise estimates following the reported results.
View the Zacks #1 Rank List
Image: Bigstock
GMED Q3 Earnings Call Highlights Guidance Cut and 2027 Reset
Key Takeaways
Globus Medical, Inc. (GMED - Free Report) lowered its 2026 revenue outlook after delayed spine product launches and a slower Nevro recovery weighed on third-quarter sales. Management shifted attention toward products and sales initiatives expected to contribute in 2027.
The earnings call also underscored a divide between near-term revenue pressure and improving profitability, with executives defending their growth strategy while acknowledging execution shortfalls.
Globus Medical Lowers 2026 Sales Outlook
Chief financial officer Kyle Kline reduced full-year revenue guidance to $3.09 billion from $3.18 billion to $3.22 billion, citing weaker third-quarter sales and early fourth-quarter trends. The revised forecast represents 5.1% annual growth.
Kline reaffirmed non-GAAP diluted earnings guidance of $4.95 to $5.05, supported by cost discipline and operating efficiencies. He said the revenue outlook implies a mid-single-digit sales decline in the fourth quarter.
GMED’s adjusted earnings of $1.23 per share beat the Zacks Consensus Estimate of $1.20. Third-quarter revenues declined to $763.7 million, which missed the Zacks Consensus Estimate of $793 million.
Globus Medical, Inc. Price, Consensus and EPS Surprise
Globus Medical, Inc. price-consensus-eps-surprise-chart | Globus Medical, Inc. Quote
GMED Faces Spine Launch and Recruiting Delays
Chief executive officer Keith Pfeil attributed U.S. Spine's 2% growth to difficult comparisons, postponed launches and smaller-than-expected contributions from competitive sales representatives. He acknowledged that execution could have been better.
During questions from BMO Capital Markets, Pfeil declined to quantify the sales lost to delayed launches. He said manufacturing problems had largely been addressed, although smaller issues remained.
A Jefferies analyst asked whether slower market growth had affected results. Pfeil instead emphasized company-specific shortcomings, including the pace of recruiting and the sales transferred by newly hired representatives.
Globus Targets 2027 Product Contributions
Pfeil outlined SCRIPT patient-specific implants and rods, the XLIF Prone Lateral Solution and the forthcoming EIQ product suite as important growth drivers. SCRIPT is available, while the prone-positioning solution is scheduled for later in the fourth quarter.
Kline clarified during the Needham question-and-answer exchange that delayed products would contribute little to 2026 revenue. Their anticipated impact has shifted into 2027.
Asked by TD Cowen about growth expectations, Pfeil described mid- to high-single-digit revenue growth as a goal, not formal 2027 guidance. He expects earnings to outpace revenue growth, although increased research and development spending will offset some margin gains.
GMED Sees Uneven Nevro Recovery
Nevro sales fell 25.7% year over year to $73.7 million and declined 9% sequentially. Pfeil said weaker trial volumes continued to restrain revenue despite substantial rehiring of sales personnel.
Kline reported a 19.9% adjusted EBITDA margin for Nevro, reflecting the benefits of previous restructuring. He said productivity improvements from newly trained representatives should support the recovery.
Pfeil identified HFX Elite, a new implantable pulse generator planned for commercial launch in the first half of 2027, as another potential catalyst. The company also intends to pursue competitive recruiting in the pain business.
Globus Expands Capital Deployment and Cash Returns
Enabling Technologies revenue grew 24% to $34.9 million. Pfeil said combined EGPS robot and eHub navigation deployments rose 73% year over year, including sold, leased and rented units, supporting a more flexible capital model.
Kline cautioned that a shift toward rental and lease arrangements would reduce upfront revenue, particularly against a demanding fourth-quarter comparison. Management expects greater recurring revenues and implant pull-through over time.
The company generated $225 million in quarterly free cash flow and repurchased approximately $143 million of shares. Kline said the board added $500 million to the repurchase authorization, while internal product development remains the first capital allocation priority.
GMED Maintains Its Longer-Term Focus
Pfeil also highlighted 19% growth in Trauma and acquisitions of Higgs Boson and Synaptive assets to develop surgical intelligence and cranial capabilities. He said those acquisitions would not contribute meaningful revenue in 2027.
Management maintained confidence in the broader product and technology strategy, while placing immediate emphasis on launch execution, sales force productivity and stabilizing Nevro. The latest outlook keeps the near-term revenue challenges in focus.
Zacks Rank and Style Scores for GMED
GMED carries a Zacks Rank #2 (Buy), reflecting a favorable earnings-estimate-revision profile under the Zacks ranking framework. Its Value Score of B, Growth Score of A and VGM Score of A indicate favorable characteristics across valuation and growth measures. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Its Momentum Score of D presents a contrasting signal, reflecting weaker momentum characteristics. Although the combination of a top-two Zacks Rank and strong VGM Score is favorable within the framework, the Zacks Rank can change as analysts revise estimates following the reported results.